Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 11, 2014, Pages 1873-1881

  Bock, Carolin ^a   Kuhn, Christina ^a   Ditsch, Nina ^a   Krebold, Regina ^a   Heublein, Sabine ^a   Mayr, Doris ^a   Doisneau Sixou, Sophie ^a,b   Jeschke, Udo ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Breast cancer; CD133; EMT; N cadherin; Stem cell

Indexed keywords

CD133 ANTIGEN; NERVE CELL ADHESION MOLECULE; TUMOR MARKER; CADHERIN; CDH2 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; BREAST TUMOR; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ANTIGENS, CD; BREAST NEOPLASMS; CADHERINS; FEMALE; GLYCOPROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84919484990     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1750-z     Document Type: Article

References (46)

1. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res BCR 11:R46. doi:10.1186/bcr2333
2. Aomatsu N et al (2012) CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS ONE 7:e45865. doi:10.1371/journal.pone.0045865
3. Armstrong AJ et al (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res MCR 9:997–1007. doi:10.1158/1541-7786.MCR-10-0490
4. Carvalho ST, Stiepcich MM, Fregnani JH, Nonogaki S, Rocha R, Soares FA (2011) Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics (Sao Paulo) 66:607–612
5. Christofori G (2006) New signals from the invasive front. Nature 441:444–450. doi:10.1038/nature04872
6. Comen EA (2012) Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med 14:97–104
7. Creighton CJ, Chang JC, Rosen JM (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15:253–260. doi:10.1007/s10911-010-9173-1
8. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13:2236–2252. doi:10.1111/j.1582-4934.2008.00455.x
9. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res BCR 14:202. doi:10.1186/bcr2938
10. ElMoneim HM, Zaghloul NM (2011) Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: an immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt. Clinics (Sao Paulo) 66:1765–1771
11. Elston EW, Ellis IO (1993) Method for grading breast cancer. J Clin Pathol 46:189–190
12. Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W (2012) Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE 7:e51136. doi:10.1371/journal.pone.0051136
13. Hay ED (1995) An overview of epithelio-mesenchymal transformation. Acta Anat 154:8–20
14. Ieni A, Giuffre G, Adamo V, Tuccari G (2011) Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas. Anticancer Res 31:1315–1320
15. Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–1694. doi:10.1093/jnci/djn389
16. Jeong H, Ryu YJ, An J, Lee Y, Kim A (2012) Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60:E87–E95. doi:10.1111/j.1365-2559.2012.04195.x
17. Jeschke U et al (2007) Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res 27:1969–1974
18. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Investig 119:1420–1428. doi:10.1172/JCI39104
19. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T (2012) Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res BCR 14:R15. doi:10.1186/bcr3099
20. King JA, Shevde LA, Ofori-Acquah S, Watkins G, Jiang WG (2008) Is N-cadherin expression important in ductal carcinoma? South Med J 101:470–475. doi:10.1097/SMJ.0b013e31816c0112
21. Levi F, Bosetti C, Lucchini F, Negri E, La Vecchia C (2005) Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev 14:497–502. doi:10.1097/00008469-200512000-00002
22. Liu Q, Li JG, Zheng XY, Jin F, Dong HT (2009) Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J 122:2763–2769
23. Liu CC, Prior J, Piwnica-Worms D, Bu G (2010) LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 107:5136–5141. doi:10.1073/pnas.0911220107
24. Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715. doi:10.1016/j.cell.2008.03.027
25. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA (2011) Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res BCR 13:202. doi:10.1186/bcr2789
26. Mizrak D, Brittan M, Alison M (2008) CD133: molecule of the moment. J Pathol 214:3–9. doi:10.1002/path.2283
27. Nadal R et al (2013) CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 133:2398–2407. doi:10.1002/ijc.28263
28. Nagi C et al (2005) N-cadherin expression in breast cancer: correlation with an aggressive histologic variant–invasive micropapillary carcinoma. Breast Cancer Res Treat 94:225–235. doi:10.1007/s10549-005-7727-5
29. Nakagawa M et al (2011) Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res 31:2389–2393
30. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. doi:10.1634/theoncologist.10-90003-20
31. Park J, Schwarzbauer JE (2013) Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. doi:10.1038/onc.2013.11810.1038/onc.2013.118
32. Patani N, Martin LA, Dowsett M (2013) Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 133:1–13. doi:10.1002/ijc.27997
33. Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365–375. doi:10.1387/ijdb.041794hp
34. Radice GL, Rayburn H, Matsunami H, Knudsen KA, Takeichi M, Hynes RO (1997) Developmental defects in mouse embryos lacking N-cadherin. Dev Biol 181:64–78. doi:10.1006/dbio.1996.8443
35. Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. doi:10.1111/joim.12084
36. Saito M, Tucker DK, Kohlhorst D, Niessen CM, Kowalczyk AP (2012) Classical and desmosomal cadherins at a glance. J Cell Sci 125:2547–2552. doi:10.1242/jcs.066654
37. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997. doi:10.1158/0008-5472.CAN-07-2017
38. Schott AF et al (2013) Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res Off J Am Assoc Cancer Res 19:1512–1524. doi:10.1158/1078-0432.CCR-11-3326
39. Singh N, Liu G, Chakrabarty S (2013) Isolation and characterization of calcium sensing receptor null cells: a highly malignant and drug resistant phenotype of colon cancer. Int J Cancer 132:1996–2005. doi:10.1002/ijc.27902
40. Stemmler MP (2008) Cadherins in development and cancer. Mol BioSyst 4:835–850. doi:10.1039/b719215k
41. Stoyianni A et al (2012) Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. Anticancer Res 32:1273–1281
42. Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release Off J Control Release Soc 171:280–287. doi:10.1016/j.jconrel.2013.07.014
43. Takebe N, Warren RQ, Ivy SP (2011) Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res BCR 13:211. doi:10.1186/bcr2876
44. van Nes JG et al (2012) Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 133:49–59. doi:10.1007/s10549-011-1684-y
45. Zhang Y et al (2012) Epithelial mesenchymal transition correlates with CD24+ CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 27:1599–1605. doi:10.3892/or.2012.1681
46. Zhao P, Lu Y, Jiang X, Li X (2011) Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 102:1107–1111. doi:10.1111/j.1349-7006.2011.01894.x